{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:58:22Z","timestamp":1789001902814,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Both B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are clinically used for diagnosing and monitoring heart failure. However, their levels are influenced by several factors, and their impacts on chronic kidney disease (CKD) patients remain unclear. This study included 1036 patients who visited the Nephrology division at our hospital between 2014 and 2015. Plasma BNP, NT-proBNP levels and the BNP\/NT-proBNP ratio were measured at each CKD stage, and their correlation with clinical factors were analyzed. This study included 1037 patients with stage 1 to stage 5D CKD (CKD 1-2,\n                    <jats:italic>n\u2009<\/jats:italic>\n                    =\u2009114; CKD 3,\n                    <jats:italic>n\u2009<\/jats:italic>\n                    =\u2009256; CKD 4,\n                    <jats:italic>n\u2009<\/jats:italic>\n                    =\u2009266; CKD 5,\n                    <jats:italic>n\u2009<\/jats:italic>\n                    =\u2009298; CKD 5D,\n                    <jats:italic>n\u2009<\/jats:italic>\n                    =\u2009102). Levels of plasma BNP and NT-proBNP levels and the NT-proBNP\/BNP ratio increased, and the correlation between BNP and NT-proBNP levels weakened with declining kidney function. Although various clinical factors were found to be significantly correlated with these parameters, multivariate analysis showed that male gender and hemoglobin, phosphate, and parathyroid hormone levels were significantly correlated with both plasma BNP and NT-proBNP levels. Notably, a higher NT-proBNP\/BNP ratio was significantly associated with increased cardiovascular events\u00a0in patients with CKD stages 4 and 5. As plasma BNP and NT-proBNP levels are influenced by various factors in patients with CKD, careful interpretation of these parameters is essential. In patients with advanced-stage CKD, the NT-proBNP\/BNP ratio may be a useful predictor of CVD development.\n                  <\/jats:p>","DOI":"10.1038\/s41440-025-02272-2","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T03:18:45Z","timestamp":1751339925000},"page":"2303-2314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative analysis of plasma BNP and NT-proBNP levels, and NT-proBNP\/BNP ratio in patients with chronic kidney disease"],"prefix":"10.1038","volume":"48","author":[{"given":"Hideki","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2272_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382:339\u201352.","journal-title":"Lancet"},{"key":"2272_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archinte.164.6.659","volume":"164","author":"DS Keith","year":"2004","unstructured":"Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659\u201363.","journal-title":"Arch Intern Med"},{"key":"2272_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jama.286.4.421","volume":"286","author":"HC Gerstein","year":"2001","unstructured":"Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421\u20136.","journal-title":"JAMA"},{"key":"2272_CR4","unstructured":"United States Renal Data System. Annual Data Report 2016: Chapter 9 \u2013 Cardiovascular Disease in Patients with ESRD. Bethesda, MD: National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; 2016."},{"key":"2272_CR5","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the american heart association. Circulation 2019;139:e840\u201378.","journal-title":"Circulation"},{"key":"2272_CR6","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jacc.2012.01.077","volume":"60","author":"C Ronco","year":"2012","unstructured":"Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol. 2012;60:1031\u201342.","journal-title":"J Am Coll Cardiol"},{"key":"2272_CR7","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.2215\/CJN.03150509","volume":"4","author":"M Saraff","year":"2009","unstructured":"Saraff M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol. 2009;4:2013\u201326.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2272_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23:352\u201380.","journal-title":"Eur J Heart Fail"},{"key":"2272_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cardfail.2023.02.009","volume":"29","author":"H Tsutsui","year":"2023","unstructured":"Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J, et al. natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the heart failure association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. J Card Fail. 2023;29:787\u2013804.","journal-title":"J Card Fail"},{"key":"2272_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ijcard.2014.08.032","volume":"176","author":"M Volpe","year":"2014","unstructured":"Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol. 2014;176:630\u20139.","journal-title":"Int J Cardiol"},{"key":"2272_CR11","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.cardfail.2005.04.019","volume":"11","author":"C Hall","year":"2005","unstructured":"Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail. 2005;11:S81\u201383.","journal-title":"J Card Fail"},{"key":"2272_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/hrt.2005.071233","volume":"92","author":"M Weber","year":"2006","unstructured":"Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006;92:843\u20139.","journal-title":"Heart"},{"key":"2272_CR13","first-page":"1016","volume":"10","author":"T Sawatani","year":"2021","unstructured":"Sawatani T, Shirakabe A, Okazaki H, Matsushita M, Shibata Y, Shigihara S, et al. Clinical significance of the N-terminal pro-brain natriuretic peptide and B-type natriuretic peptide ratio in the acute phase of acute heart failure. Eur Heart J Acute Cardiovasc Care. 2021;10:1016\u201326.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2272_CR14","doi-asserted-by":"crossref","unstructured":"Neuen BL, Vaduganathan M, Claggett BL, Beldhuis I, Myhre P, Desai AS, et al. Natriuretic peptides, kidney function, and clinical outcomes in heart failure with preserved ejection fraction. JACC Heart Fail. 2024;13:28\u201339.","DOI":"10.1016\/j.jchf.2024.08.009"},{"key":"2272_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jacc.2005.08.051","volume":"47","author":"S Anwaruddin","year":"2006","unstructured":"Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91\u201397.","journal-title":"J Am Coll Cardiol"},{"key":"2272_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cccn.2005.03.009","volume":"358","author":"MS Willis","year":"2005","unstructured":"Willis MS, Lee ES, Grenache DG. Effect of anemia on plasma concentrations of NT-proBNP. Clin Chim Acta. 2005;358:175\u201381.","journal-title":"Clin Chim Acta"},{"key":"2272_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/ejhf.2393","volume":"24","author":"RIS Alnuwaysir","year":"2022","unstructured":"Alnuwaysir RIS, Grote Beverborg N, Hoes MF, Markousis-Mavrogenis G, Gomez KA, van der Wal HH, et al. Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. Eur J Heart Fail. 2022;24:192\u2013204.","journal-title":"Eur J Heart Fail"},{"key":"2272_CR18","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.2215\/CJN.01660216","volume":"11","author":"K Untersteller","year":"2016","unstructured":"Untersteller K, Girerd N, Duarte K, Rogacev KS, Seiler-Mussler S, Fliser D, et al. NT-proBNP and echocardiographic parameters for prediction of cardiovascular outcomes in patients with CKD Stages G2-G4. Clin J Am Soc Nephrol. 2016;11:1978\u201388.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2272_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10157-016-1363-8","volume":"21","author":"H Fujii","year":"2017","unstructured":"Fujii H, Joki N. Mineral metabolism and cardiovascular disease in CKD. Clin Exp Nephrol. 2017;21:53\u201363.","journal-title":"Clin Exp Nephrol"},{"key":"2272_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1681\/ASN.2014010108","volume":"26","author":"N Bansal","year":"2015","unstructured":"Bansal N, Hyre Anderson A, Yang W, Christenson RH, deFilippi CR, Deo R, et al. High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Soc Nephrol. 2015;26:946\u201356.","journal-title":"J Am Soc Nephrol"},{"key":"2272_CR21","doi-asserted-by":"publisher","first-page":"100725","DOI":"10.1016\/j.xkme.2023.100725","volume":"5","author":"MP Schneider","year":"2023","unstructured":"Schneider MP, Schmid M, Nadal J, Krane V, Saritas T, Busch M, et al. Copeptin, natriuretic peptides, and cardiovascular outcomes in patients With CKD: the German Chronic Kidney Disease (GCKD) study. Kidney Med. 2023;5:100725.","journal-title":"Kidney Med"},{"key":"2272_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ahj.2023.05.014","volume":"264","author":"B Ozkan","year":"2023","unstructured":"Ozkan B, Grams ME, Coresh J, McEvoy JW, Echouffo-Tcheugui JB, Mu SZ, et al. Associations of N-terminal pro-B-type natriuretic peptide, estimated glomerular filtration rate, and mortality in US adults. Am Heart J. 2023;264:49\u201358.","journal-title":"Am Heart J"},{"key":"2272_CR23","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2215\/CJN.00850208","volume":"3","author":"R Tagore","year":"2008","unstructured":"Tagore R, Ling LH, Yang H, Daw HY, Chan YH, Sethi SK. Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1644\u201351.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2272_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cccn.2005.05.021","volume":"361","author":"C Chenevier-Gobeaux","year":"2005","unstructured":"Chenevier-Gobeaux C, Claessens YE, Voyer S, Desmoulins D, Ekindjian OG. Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the Emergency Department: comparison with brain natriuretic peptide (BNP). Clin Chim Acta. 2005;361:167\u201375.","journal-title":"Clin Chim Acta"},{"key":"2272_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1053\/j.ajkd.2021.06.017","volume":"79","author":"N Bansal","year":"2022","unstructured":"Bansal N, Zelnick LR, Ballantyne CM, Chaves PHM, Christenson RH, Coresh J, et al. Upper reference limits for high-sensitivity cardiac troponin T and N-Terminal fragment of the prohormone brain natriuretic peptide in patients with CKD. Am J Kidney Dis. 2022;79:383\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2272_CR26","doi-asserted-by":"publisher","first-page":"e23872","DOI":"10.1097\/MD.0000000000023872","volume":"99","author":"S Yi","year":"2020","unstructured":"Yi S, Chen M. Decreased albumin is associated with elevated N-terminal pro-brain natriuretic peptide and poor long-term prognosis in patients with chronic heart failure. Medicine 2020;99:e23872.","journal-title":"Medicine"},{"key":"2272_CR27","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1006\/jmcc.1999.1030","volume":"31","author":"E Harada","year":"1999","unstructured":"Harada E, Nakagawa O, Yoshimura M, Harada M, Nakagawa M, Mizuno Y, et al. Effect of Interleukin-1\u03b2 on cardiac hypertrophy and production of natriuretic peptides in rat cardiocyte culture. J Mol Cell Cardiol. 1999;31:1997\u20132006.","journal-title":"J Mol Cell Cardiol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02272-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02272-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02272-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T09:13:09Z","timestamp":1762333989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02272-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2272"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02272-2","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was partly supported by Roche Diagnostics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}